Total Cholesterol, High Density Lipoprotein and Triglyceride for Cardiovascular Disease in Elderly Patients Treated with Metformin

다국어 초록 (Multilingual Abstract)

Metformin reduces total cholesterol level, low density lipoprotein cholesterol (LDL-C) level, blood glucose level and increases high density lipoprotein cholesterol (HDL-C) level associated with cardiovascular disease. We evaluated effect of metformin on lipid profile in Korean patients with type 2 diabetes aged 64 yeras or older. We retrospectively examined 307 outpatients treated with metformin in a hospital setting with a follow-up period of 4.7 years. Metformin was not associated with the improvement in total cholesterol level (adjusted mean difference; 30.6 mg/dl, 95% CI: 24.9 to 36.4) and HDL-C level (adjusted mean difference; 2.6 mg/dl, 95% CI: 0.09 to 4.64) but may be associated with improvement in triglyceride level (adjusted mean difference; 41.5 mg/dl, 95% CI: 24.7 to 58.3). In comparison to the placebo groups (Kooy et al., 2009), there was a 1.5-fold decrease in triglyceride level and a 2-fold decrease in HDL-C level in our study. The frequency of Scr level that increased above the defined level [Scr ≥ 1.5 mg/dl for male, ≥1.4 mg/dl for female] was 6.7% [mean difference of elevated Scr: −0.9 mg/dl, 95% CI: −0.41 to −1.44, p < 0.002]. To confirm the efficacy of metformin use on triglyceride level and HDL-C level associated with the risk of cardiovascular disease in patient with diabetes, further placebo-controlled investigations are required.

참고문헌 (Reference)

1 Stern, M. P., "The effect of glycemic control on the incidence of macrovascular complications of type2 diabetes" 7 : 155-162, 1998

2 Ryden, L., "Task force on diabetes cardiovascular diseases guideline on diabetes, pre-diabetes, and cardiovascular disease" 72-, 2007

3 Psaty, B. M., "Surrogate end points and FDA approval" 299 : 1474-1476, 2008

4 "Summary of revisions for the 2009: clinical practice recommendations" 32 : S3-S5, 2009

5 Turner, R. C., "Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United kingdom prospective diabetes study (UKPDS23)" 316 : 823-828, 1998

6 Coresh, J., "Prevalence of high blood pressure and elevated serum creatinine level in the United States" 161 : 1207-1216, 2001

7 Culleton, B. F., "Prevalence and correlates of elevated serum creatine levels" 159 : 1785-1790, 1999

8 Hemmingsen, B., "Oral hypoglycemic agent, insulin resistance and cardiovascular disease in patients with type 2 diabetes" 161 : 1-9, 2009

9 Nordestgaard, B. G., "Non-fasting triglyceride and risk of MI, ischemic heart disease, and death in men and women" 298 : 299-308, 2007

10 Warnick, G. R., "National cholesterol education program recommendations for measurement of highdensity lipoprotein-cholesterol: executive summary. The national cholesterol education program working group on lipoprotein measurement" 41 : 1427-1433, 1995

11 Bailey, C. J., "Metformin: effect on micro and macrovascular complications in type2 diabetes" 22 : 215-224, 2008

12 Di Angelantonio, E., "Major lipids, apolipoproteins, and risk of vascular disease" 302 : 1993-2000, 2009

13 Kooy, A., "Long term effect of metformin on metabolism and microvascullar and macrovascular disease" 169 : 616-625, 2009

14 National kidney foundation (K/DOQI), "K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients" 45 : S1-S153, 2005

15 Sone, H., "Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients" 28 : 1463-1471, 2005

16 Sniderman, A. D., "Hypertriglyceridemic hyperapo B: The unappreciated atherogenic dyslipoproteinemia in tye 2 diabetes mellitus" 135 : 447-459, 2001

17 Weverling-Rijnsburger, A. W., "High density vs low density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age" 163 : 1549-1554, 2003

18 Corti, M. C., "High density lipoprotein cholesterol predicts coronary heart disease mortality in older persons" 274 : 539-544, 1995

19 Turner, R. C., "Glycemic control with diet, sulfonylurea, metformin, or insulin inpatients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)" 281 : 2005-2012, 1999

20 Selvin, E., "Glycemic control and coronary heart disease risk in persons with and without diabetes" 165 : 1910-1916, 2005

21 Bristol-myers squibb company, "Glucophage and Glucophage XR prescribing information"

22 Simmons, R. K., "Evaluation of the Framingham risk score in the European prospective investigation of cancer-norfolk cohort" 168 : 1209-1216, 2008

23 DeFronzo, R. A., "Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus" 333 : 541-549, 1995

24 Pradhan, A. D., "Effect of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes" 302 : 1186-1194, 2009

25 Beckman, J. A., "Diabetes and atherosclerosis, epidemiology, pathophysiology, and management" 287 : 2570-2581, 2002

26 Roper, N. A., "Cause-specific mortality in a population with diabetes" 25 : 43-48, 2002

27 Selvin, E., "Cardiovascular outcomes in trial of oral diabetes medications" 168 : 2070-2080, 2008

28 Hunt, S. A., "ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult, in A report of the ACC/AHA task force on practice guideline (trunk)" American College of Cardiology foundation (ACCF) 82-, 2005